Insulin degludec
| Clinical data | |
|---|---|
| Trade names | Tresiba |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a615055 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | 30–90 minutes |
| Duration of action | ≤ 42 hours |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem SID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C274H411N65O81S6 |
| Molar mass | 6104.04 g·mol−1 |
| (what is this?) (verify) | |
Insulin degludec (INN/USAN) is an ultralong-acting basal insulin analogue that was developed by Novo Nordisk under the brand name Tresiba.[7] It is administered via subcutaneous injection to help control the blood sugar level of those with diabetes. It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin,[8][9][10] that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins.
Insulin degludec is a modified insulin that has one single amino acid deleted in comparison to human insulin, and is conjugated to hexadecanedioic acid via gamma-L-glutamyl spacer at the amino acid lysine at position B29.
It is included on the World Health Organization's List of Essential Medicines[11] as an equivalent to insulin glargine. In 2022, it was the 138th most commonly prescribed medication in the United States, with more than 4 million prescriptions.[12][13]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 9 April 2023.
- ^ https://www.tga.gov.au/resources/publication/scheduling-decisions-final/scheduling-delegates-final-decisions-january-2018/111-insulin-deglude
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
- ^ "Diabetic health". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ "Tresiba- insulin degludec injection, solution". DailyMed. 1 July 2022. Archived from the original on 7 July 2022. Retrieved 11 February 2024.
- ^ "Tresiba EPAR". European Medicines Agency. 17 September 2018. Archived from the original on 22 January 2021. Retrieved 15 January 2021.
- ^ Cite error: The named reference
CHMP2012was invoked but never defined (see the help page). - ^ Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T (May 2007). "Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes". Diabetes, Obesity & Metabolism. 9 (3): 290–299. doi:10.1111/j.1463-1326.2006.00685.x. PMID 17391154. S2CID 23810204.
- ^ Haahr H, Heise T (September 2014). "A review of the pharmacological properties of insulin degludec and their clinical relevance". Clinical Pharmacokinetics. 53 (9): 787–800. doi:10.1007/s40262-014-0165-y. PMC 4156782. PMID 25179915.
- ^ "Tresiba Summary of product characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 4 March 2016. Retrieved 29 September 2014.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Insulin Degludec Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.